CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE CSSi

GLEN BURNIE, Md., Aug. 19, 2014 /PRNewswire/ -- CSSi, the leader in patient recruitment solutions for the clinical research industry, recently announced the formation of the company's Medical and Clinical Advisory Board ("MCAB") and is pleased to announce the addition of Dr. William E. Gannon, Jr. to the MCAB.

Photo - http://photos.prnewswire.com/prnh/20140818/136957

The MCAB, with Dr. Gannon's leadership, will help provide insight across a variety of therapeutic areas and set strategic goals for the advancement and development of CSSi's work within the clinical research industry to shorten the timelines of getting new drugs and devices to market. Additionally, MCAB utilizes best practices to achieve optimum outcomes of clinical trials to support product labeling. Dr. Gannon joins Dr. Ronald Bukowski who was appointed as Chairman of the MCAB in June.

The MCAB works in partnership with CSSi's newly formed LifeSciences division which provides innovative solutions which span the entire lifecycle of a new drug or device by reducing time to market, development costs, and resources. Their portfolio of service offerings includes Health Authority Interactions, regulatory and clinical consulting, FDA/EMEA Advisory Committee Support, clinical and site planning services, and regulatory and clinical communications services. Since 2005, the LifeSciences team members have over 50 successful NDA/BLA submissions, and have worked on more than 400 new drugs, biologics, and devices.

William E. Gannon, Jr., M.D., serves as Chief Scientific Officer & Medical Director for Capital City Technical Consulting (CCTC) in Washington, DC. In addition to receiving his medical training and clinical work at Ross University, Case Western Reserve and George Washington University, Dr. Gannon obtained an M.B.A. at George Washington University in 1988 and has since built a wealth of experience in the management of clinical trials including designing the trials and building operational teams to ensure their successful completion. Dr. Gannon has held positions in multinational Clinical Research Organizations, medical device, biotech and pharmaceutical firms. In his most recent position prior to CCTC, Inc., Dr, Gannon served as Vice President – Clinical & Medical Affairs in the biotechnology arena. Dr. Gannon's primary focus has been on oncology therapeutic and diagnostic applications, but possesses a board range of experience across therapeutic categories. Dr. Gannon has managed clinical trials and operations as well as the design, corporate and regulatory strategies, regulatory submissions and execution of Phase I through Phase IV clinical trials in the U.S., Europe and Asia. Additionally, Dr. Gannon is involved in philanthropy in the Washington, DC area and currently serves on the Board of Directors for the Engineering World Health Organization and The Foundation for Sickle Cell Research.

"We are thrilled to have Dr. Gannon join our MCAB," shared Jim Sergi, President of CSSi LifeSciences. "We anticipate that his experience and expert guidance will play a critical role in guiding our work and developing innovative products in all areas of the life sciences industry. Dr. Gannon will bring additional medical insight into patient pathways, protocol analysis, enrollment feasibility and the identification of global regulatory challenges." Dr Gannon commented, "I am quite pleased to be asked to serve and look forward to being part of CSSi's MCAB."

Additional physicians will be added in the near future, allowing for expansion of global regulatory specialties and therapeutic diversity which will reflect the international leadership position of CSSi in the patient recruitment industry.

About CSSi
CSSi delivers global solutions that ensure successful enrollment, on time, every time. Through its innovative enrollment planning and full-service patient recruitment solutions, CSSi is able to reduce the costs and timelines associated with recruitment of subjects for clinical studies. CSSi is the only patient recruitment company with a worldwide team of Local Enrollment Specialists (LES), on the ground, close to sites and able to meet your study's recruitment goals on time. Our Local Enrollment Specialists are certified, highly experienced study coordinators located across the globe. 

CSSi has a commitment and passion for finding life cycle solutions to bring drugs or devices to market quickly by reducing development costs and resources. Our vision is to ensure that the best possible medicines and devices reach patients as quickly as possible.?

For more information on CSSi, visit www.CSSiEnroll.com, or contact Kristina Astle at Email or 443-308-5827.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

310 Broadway
Cape Girardeau, MO 63701

FCC Public File
publicfile@kfvs12.com
573-335-1212
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KFVS12. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.